|1.||Suzuki, Koji: 2 articles (01/2013 - 01/2003)|
|2.||Khaw, Kay-Tee: 1 article (12/2014)|
|3.||Vergnaud, Anne-Claire: 1 article (12/2014)|
|4.||Duarte-Salles, Talita: 1 article (12/2014)|
|5.||Aleksandrova, Krasimira: 1 article (12/2014)|
|6.||María Huerta, José: 1 article (12/2014)|
|7.||Skeie, Guri: 1 article (12/2014)|
|8.||Cadeau, Claire: 1 article (12/2014)|
|9.||Klinaki, Eleni: 1 article (12/2014)|
|10.||Hulshof, Paul J M: 1 article (12/2014)|
01/01/1988 - "Animals fed canthaxanthin presented a notably and statistically significant reduction in tumor number and size compared with controls. "
09/01/2008 - "Partially saturated canthaxanthin purified from Aspergillus carbonarius induces apoptosis in prostrate cancer cell line."
08/01/1998 - "For canthaxanthin, there are no published data regarding associations with cancer risk. "
02/01/1998 - "Canthaxanthin induces apoptosis in human cancer cell lines."
01/01/1997 - "Male or female mice received two different doses of canthaxanthin (7 or 14 micrograms/g body wt/day) starting 15 days before tumor inoculation (7 x 10(7) cells i.p.). "
|2.||Thymoma (Thymic Carcinoma)
01/01/1997 - "Our study shows the antitumor efficacy of canthaxanthin in vivo against a transplantable murine thymoma and points out the importance of dose, administration timing, and sex in the antitumor efficacy of this compound."
01/01/1997 - "Canthaxanthin was incorporated in a dose-dependent manner in liver and thymoma cells and to a larger extent in females than in males. "
01/01/1997 - "The antitumor effect of canthaxanthin in BALB/c mice bearing a transplantable thymoma was investigated. "
01/01/1997 - "Antitumor effect of an oral administration of canthaxanthin on BALB/c mice bearing thymoma cells."
|3.||beta-Thalassemia (Cooley's Anemia)
|4.||Urinary Bladder Neoplasms (Bladder Cancer)
01/01/1982 - "A review of published trials with beta-carotene and/or canthaxanthin treatment of erythropoietic protoporphyria is presented. "
10/01/1998 - "The present case illustrates the effectiveness of beta-carotene associated with canthaxanthin in erythropoietic protoporphyria."
01/01/1979 - "36 patients from 19 families with erythropoietic protoporphyria were treated for about 5 years during the summer months with beta-carotene alone or beta-carotene plus canthaxanthin in daily doses of 50-200 mg. The effect of the treatment was evaluated clinically on the basis of information provided by the patients regarding the period of time they could stay in the sun. "
01/01/1986 - "Twenty-five patients (erythropoietic protoporphyria 23, polymorphous light eruption 1, "cosmetics" 1) were re-examined 2-10 months after therapy with beta-carotene and canthaxanthine was discontinued. "
|1.||beta Carotene (Betacarotene)
|3.||Vitamin A (Retinol)
|5.||retinol palmitate (retinyl palmitate)
|6.||Tretinoin (Retinoic Acid)
|4.||Photochemotherapy (Photodynamic Therapy)